Zostavax is vaccine developed to prevent herpes zoster and its complications (primarily postherpetic neuralgia) in older adults. It contains a higher titer of live, attenuated virus than other varicella vaccines intended for children and younger adults. It increases cell-mediated immunity against varicella zoster virus (VZV) in elderly adults who may have had waning immunity with age.